药明康德(02359)下跌2.07%，报35.55元/股

金融界04-30

4月30日，药明康德(02359)盘中下跌2.07%，截至15:57，报35.55元/股，成交3.05亿元。无锡药明康德新药开发股份有限公司是一家全球领先的一体化新药研发和生产服务提供商，主要通过其“CRDMO”和“CTDMO”业务模式，为全球生物医药行业提供包括化学药研发和生产、生物学研究、临床前测试和临床试验研究、细胞及基因疗法研发、测试和生产等在内的全方位服务。至2022年，公司已与全球30...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2431629783?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-30 15:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2431629783","market":"hk","top_or_hot":-1,"title":"药明康德(02359)下跌2.07%，报35.55元/股","media":"金融界","content":"<div>\n<p>4月30日，药明康德(02359)盘中下跌2.07%，截至15:57，报35.55元/股，成交3.05亿元。无锡药明康德新药开发股份有限公司是一家全球领先的一体化新药研发和生产服务提供商，主要通过其“CRDMO”和“CTDMO”业务模式，为全球生物医药行业提供包括化学药研发和生产、生物学研究、临床前测试和临床试验研究、细胞及基因疗法研发、测试和生产等在内的全方位服务。至2022年，公司已与全球30...</p>\n\n<a href=\"https://hk.jrj.com.cn/2024/04/30155740493474.shtml\">网页链接</a>\n\n</div>\n","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>药明康德(02359)下跌2.07%，报35.55元/股</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n药明康德(02359)下跌2.07%，报35.55元/股\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-30 15:57 北京时间&nbsp;&nbsp;&nbsp;<a href=https://hk.jrj.com.cn/2024/04/30155740493474.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4月30日，药明康德(02359)盘中下跌2.07%，截至15:57，报35.55元/股，成交3.05亿元。无锡药明康德新药开发股份有限公司是一家全球领先的一体化新药研发和生产服务提供商，主要通过其“CRDMO”和“CTDMO”业务模式，为全球生物医药行业提供包括化学药研发和生产、生物学研究、临床前测试和临床试验研究、细胞及基因疗法研发、测试和生产等在内的全方位服务。至2022年，公司已与全球30...</p>\n\n<a href=\"https://hk.jrj.com.cn/2024/04/30155740493474.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1141","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://hk.jrj.com.cn/2024/04/30155740493474.shtml","article_id":"2431629783","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2431629783","pubTimestamp":1714463824,"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"4月30日，药明康德盘中下跌2.07%，截至15:57，报35.55元/股，成交3.05亿元。至2022年，公司已与全球30多个国家的6000多家合作伙伴开展研发创新项目，被MSCI评为ESGAA级，致力于实现“让天下没有难做的药,难治的病”的愿景。截至2024年一季报，药明康德营业总收入79.82亿元、净利润19.42亿元。4月29日，公司以每股42.95-45.01人民币回购45.21万股,回购金额2005万人民币。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603259":"药明康德","BK1141":"生命科学工具和服务","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","BK1576":"医药外包概念","LU0052750758.USD":"富兰克林中国基金A Acc","02359":"药明康德","BK1583":"高瓴概念","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU1046422090.SGD":"Fidelity Pacific A-SGD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","BK0216":"研究试验","LU1997245177.USD":"安联神洲A股基金"},"translate_title":"WuXi AppTec (02359) fell 2.07% to 35.55 yuan per share","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603259":1,"02359":1},"content_text":"4月30日，药明康德(02359)盘中下跌2.07%，截至15:57，报35.55元/股，成交3.05亿元。无锡药明康德新药开发股份有限公司是一家全球领先的一体化新药研发和生产服务提供商，主要通过其“CRDMO”和“CTDMO”业务模式，为全球生物医药行业提供包括化学药研发和生产、生物学研究、临床前测试和临床试验研究、细胞及基因疗法研发、测试和生产等在内的全方位服务。至2022年，公司已与全球30多个国家的6000多家合作伙伴开展研发创新项目，被MSCI评为ESG(环境、社会及管治)AA级，致力于实现“让天下没有难做的药,难治的病”的愿景。截至2024年一季报，药明康德营业总收入79.82亿元、净利润19.42亿元。4月29日，公司以每股42.95-45.01人民币回购45.21万股,回购金额2005万人民币。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2431629783"}